Sarah Ankri

Hemarina SA operates as a biotechnology company which develops oxygen carrier for therapeutic and industrial applications. It offers organ preservation, wound healing, hemoglobin oxygen-carrier, cell culture and bioproduction and other perspective products. The company was founded by Franck Zal, Elisabeth Leize, Morgane Rousselot and Laurent Meijer on March 26, 2007 and is headquartered in Morlaix, France.

Olgram SAS provides scientific research and development services. The company is based in Brehan, France. The French company was founded by Hervé Balusson, Maryvonne Hiance, Karim Asehnoune, Pi Nyvall Collén, Pierre Rocheteau. Pierre Rocheteau has been the CEO since incorporation.

CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France.

Atlanpole Biotherapies provides immunotherapy, regenerative medicine, and radio pharmacy bio cluster services. The company is based in Nantes, France.

Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France.

Trophos SA engages in manufacturing and development of pharmaceutical products. It offers medicines to patients with conditions such as amyotrophic lateral sclerosis, spinal muscular atrophy and cardiac ischemia reperfusion injury. The company was founded by Antoine Beret and Michel Delaage in 1991 and is headquartered in Marseille, France.

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Tc Land Expression SA operates as a molecular diagnostic company. It focuses on the development and commercialisation of tests aimed at monitoring patients with immunological conditions. The firm specializes in the area of organ transplantation and immune mediated disorders. Its development programs encompass RA-INF-Dx, IMD Dx2, IMD Dx3, and L-TolX. The company was founded by Marina Guillet and Alain Huriez in November 2002 and is headquartered in Huningue, France.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

LFB Biotechnologies SASU provides plasma-derived medicinal products. The firm undertakes research and development programs in plasma fractions and biotechnologies in the areas of autoimmune diseases and hemostasis disorders. The company was founded on September 21, 2006 and is headquartered in Courtaboeuf, France.

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The company is based in Kirkland, Canada.

Investissement pour le Développement des Entreprises l'Emploi is designed to invest in small and mid cap companies based in the Pays de la Loire region of France. The fund will invest mainly in innovative companies with a profitable track record and help them in their growth by taking minority participation.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Loxbridge Research LLP operates as an investment and project management company. It specializes in startup, early stage, and later stage investments in growth stage companies. The firm supports scientists and focuses on sectors like science, medicine and healthcare technology particularly biotech, med-tech, noval therapeutic, diagnostics, cancer, infectious diseases, neurodegeneration, imaging hardware and software, and enabling devices. The company was founded by Charles Roberts in 2008 and is headquartered in London, the United Kingdom.

Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers.

Part of Valneva SE, Valneva UK Ltd. provides health care services. The company is based in London, UK and was founded in 2015.

Resolys Bio, Inc. operates as a pharmaceutical company. The firm develops OSLO and MCC for the treatment of certain forms of traumatic brain injury and chronic painful tissue disorders. The company is headquartered in Delanson, NY.

Natixis SA (Broker) is the securities brokerage division of Natixis SA (EPA: KN), a corporate and investment bank headquartered in Paris, France. They are ultimately owned by BCPE SA. The firm provides full spectrum of broking services to various investors.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

ODDO BHF SE provides banking and financial services. It specializes in private banking, asset management, as well as corporate and investment banking. The company was founded in 1854 and is headquartered in Frankfurt, Germany.

Mainstay Medical Holdings Plc is a medical device company, which focuses on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain. The company was founded in 2020 and is headquartered in Dublin, Ireland.

Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014.

Imophoron Ltd. is an American company that specializes in cutting-edge vaccine development. The company's scientific advisory board consists of world-leading experts in vaccine technology and infectious diseases. The company is constantly exploring new and innovative ways to combat infection using the latest techniques from science and technology. More information about the company can be found on their website at www.imophoron.com. The company was founded by Fred Garzoni and Richard Edward Bungay has been the CEO of the company since 2022.